Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 9/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SPR | P35270 | 1/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5149351 | 0.88 | ANO1 (0.41) | ANO1 | |
| SCHEMBL4031721 | 0.85 | HTR1A (0.39) | HTR1ASLC6A4NOTUMMTNR1AMTNR1B | |
| SCHEMBL4035538 | 0.83 | ADAM17 (0.38) | HTR1ASLC6A4NOTUMMTNR1AMTNR1B | |
| SCHEMBL3935484 | 0.82 | HTR2A (0.41) | HTR1ASLC6A4NOTUMMTNR1AMTNR1B | |
| SCHEMBL4033963 | 0.81 | MPO (0.46) | HTR1ASLC6A4NOTUMMTNR1AMTNR1B | |
| SCHEMBL4034241 | 0.80 | ADAM17 (0.36) | HTR1ASLC6A4NOTUMMTNR1AMTNR1B | |
| SCHEMBL4035244 | 0.77 | SCN8A (0.39) | HTR1ASLC6A4NOTUMMTNR1AMTNR1B | |
| SCHEMBL4029367 | 0.76 | SCN8A (0.38) | HTR1ASLC6A4NOTUMMTNR1AMTNR1B | |
| SCHEMBL4034270 | 0.75 | KMT2A (0.46) | ANO1 | |
| SCHEMBL5149429 | 0.73 | KDM4E (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2019102-A1 | Alkylacetylene substituted Acyltryptophanols | Bayer Schering Pharma AG (DE) | 2009-01-28 | — | — | EP | disclosed |
| US-20070060573-A1 | Acyltryptophanols | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060573-A1 | Acyltryptophanols | FSHR, NPY1R, NPY2R | HTR1A 8/4885SLC6A4 378/4885NOTUM 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.